# Humatrix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/humatrix

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Total disclosed funding: $14M
- Latest round: Series A (Jun 12, 2026)
- Investors on record: 8

## About

Based in Suzhou, China and founded in 2021, Humatrix Medical Technology (Suzhou) Co., Ltd., trading as Humatrix, operates as a medicine technology developer that engages in the research and development of tissue engineering and regenerative medicine technology platforms. The company's founder, Xuefeng Qiu, is a member of the American Society for Biomedical Engineering and the Cardiovascular Surgery Branch of the Chinese Medical Association. In June 2026, Humatrix raised a Series A++ funding led by BOC International (China), with participation from Suzhou Capital Group.

The company provides a tissue engineering and regenerative medicine technology platform. The core product pipeline is a small-caliber (inner diameter = 6 mm) tissue-engineering blood vessel that is suitable for the establishment of vascular access for chronic renal failure dialysis, vascular replacement for lower extremity arterial trauma, lower extremity atherosclerosis, and coronary heart disease bypass surgery. Its products include allogeneic regenerative medicine products, such as tissue-engineered ureters, tissue-engineered heart valves, nerve repair catheters, and decellularized tissues and organs.

The company generates revenue through the development and manufacture of artificial organ-based pharmaceutical products.

The Series A++ funding raised in June 2026 will primarily be used for the company's core product research and development, further accelerating the clinical research and product registration of LineMartrix® bio-artificial blood vessels.

## Funding rounds

- Series A, Jun 12, 2026 — Suzhou Capital Group, BOC International (China)
- Series A, Dec 29, 2025, $14M — IDG Capital, TTGG Ventures, Suzhou International Development Venture Capital Holding, Puhua Capital, Shanghai Healthcare Capital
- Series A, Aug 16, 2024 — IDG Capital, Huafang Capital, Shanghai Healthcare Capital
- Angel, Jun 30, 2022 — Huafang Capital

## Investors

- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Angel, Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series A
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series A
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Suzhou Capital Group — Series A
- BOC International (China) (https://capitalatlas.ai/funds/boc-international-china) — Series A